- Email: [email protected]
5466681 Receptor conjugates for targeting penicillin antibiotics to bacteria
PATENT ABSTRACTS
PCT No. PCT/JP92/00275 Sec. 371 Date Feb. 19, 1993 Sec. 102(e) Date Feb. 19, 1993 PCT Filed Mar. 7, 1992 PCT Pub. No. WO93/18061 PCT Pub. Date Sep. 16, There is disclosed an 1993. immunostimulatory agent comprising a peptide derived from lactoferrin having activity to modulate the release of inflammatory mediators from cells of the immune system. The peptide promotes the B4 from release of leukotriene polymorphonuclear neutrophils induced by activators such as the calcium ionophor A23 187, It also promotes the release of
histamine from mast cells induced by activators such as alpha-toxin-producing Staphylococcus aureus cells or the calcium ionophor A23 187. The peptide is effective at low concentrations within the range of 1 to 100 ppm. By promoting the release of such inflammatory mediators the peptide can potentiate the cellular immune response and stimulate the host defense against infectious disease. This newly discovered immunostimulatory agent is useful as an active component of pharmaceuticals, hygiene products, clinical foods, etc., for prevention and treatment of bacterial, fungal, and viral infectious in humans and animals.
5466672
THERAPEUTIC USE OF CLOSTRIDIUM DIFFICILE TOXIN A Kushnaryov Vladimir M; Redlich Philip N; Grossberg Sidney E; Sedmak J Jame Milwaukee, WI, UNITED STATES assigned to Ophidian Pharmaceuticals Inc Methods for treating cancer are described, including methods for treating colon and pancreatic cancer. Bacterial toxins and portions of bacterial toxins are employed as both diagnostic and therapeutic agents.
225
5466681 RECEPTOR CONJUGATES FOR TARGETING PENICILLIN ANTIBIOTICS TO BACTERIA Krivan Howard C; Blomberg A Lennart I Derwood, MD, UNITED STATES assigned to MicroCarb Inc A variety of conjugates useful for the treatment of infections due to pathogenic microorganisms are provided. The conjugates comprise at least one agent coupled to a receptor which binds a microorganism. Suitable agents include anti-infectives, such as antibiotics and synthetic drugs. The present invention also provides methods for treating infections in warm-blooded animals due to pathogenic microorganisms.
5466685 INHIBITION OF EXPRESSION OF BETA-LACTAMASE USING ESTERS OF FATTY ACID ALCOHOLS Brown-Skrobot Susa; Novick Richard P; Projan Steven J Hamilton, NJ, UNITED STATES assigned to Johnson & Johnson A class of chemical compounds comprising fatty acid ester derivatives used to inhibit beta-lactamase production by infectious bacteria. These inhibitors have been found to retard the resistance of certain strains of bacteria to beta-lactam antibiotics, such as penicillin, by interfering with the transcription of the beta-lactamase gene and precluding expression of beta-lactamase. In accordance therewith, these inhibitors permit effective treatment of infections of resistive otherwise bacteria with antibiotics.
PCT No. PCT/JP92/00275 Sec. 371 Date Feb. 19, 1993 Sec. 102(e) Date Feb. 19, 1993 PCT Filed Mar. 7, 1992 PCT Pub. No. WO93/18061 PCT Pub. Date Sep. 16, There is disclosed an 1993. immunostimulatory agent comprising a peptide derived from lactoferrin having activity to modulate the release of inflammatory mediators from cells of the immune system. The peptide promotes the B4 from release of leukotriene polymorphonuclear neutrophils induced by activators such as the calcium ionophor A23 187, It also promotes the release of
histamine from mast cells induced by activators such as alpha-toxin-producing Staphylococcus aureus cells or the calcium ionophor A23 187. The peptide is effective at low concentrations within the range of 1 to 100 ppm. By promoting the release of such inflammatory mediators the peptide can potentiate the cellular immune response and stimulate the host defense against infectious disease. This newly discovered immunostimulatory agent is useful as an active component of pharmaceuticals, hygiene products, clinical foods, etc., for prevention and treatment of bacterial, fungal, and viral infectious in humans and animals.
5466672
THERAPEUTIC USE OF CLOSTRIDIUM DIFFICILE TOXIN A Kushnaryov Vladimir M; Redlich Philip N; Grossberg Sidney E; Sedmak J Jame Milwaukee, WI, UNITED STATES assigned to Ophidian Pharmaceuticals Inc Methods for treating cancer are described, including methods for treating colon and pancreatic cancer. Bacterial toxins and portions of bacterial toxins are employed as both diagnostic and therapeutic agents.
225
5466681 RECEPTOR CONJUGATES FOR TARGETING PENICILLIN ANTIBIOTICS TO BACTERIA Krivan Howard C; Blomberg A Lennart I Derwood, MD, UNITED STATES assigned to MicroCarb Inc A variety of conjugates useful for the treatment of infections due to pathogenic microorganisms are provided. The conjugates comprise at least one agent coupled to a receptor which binds a microorganism. Suitable agents include anti-infectives, such as antibiotics and synthetic drugs. The present invention also provides methods for treating infections in warm-blooded animals due to pathogenic microorganisms.
5466685 INHIBITION OF EXPRESSION OF BETA-LACTAMASE USING ESTERS OF FATTY ACID ALCOHOLS Brown-Skrobot Susa; Novick Richard P; Projan Steven J Hamilton, NJ, UNITED STATES assigned to Johnson & Johnson A class of chemical compounds comprising fatty acid ester derivatives used to inhibit beta-lactamase production by infectious bacteria. These inhibitors have been found to retard the resistance of certain strains of bacteria to beta-lactam antibiotics, such as penicillin, by interfering with the transcription of the beta-lactamase gene and precluding expression of beta-lactamase. In accordance therewith, these inhibitors permit effective treatment of infections of resistive otherwise bacteria with antibiotics.